ArticlesPrevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study
Introduction
Heart failure and left-ventricular systolic dysfunction are increasingly important disorders that are linked to poor outlook, poor quality of life, and some of the highest health-care costs for one disorder.1 Annual mortality attributable to severe heart failure is around 60%.2 In the general population, in which all grades of heart failure are represented, 5-year mortality is 50–75%,3 and morbidity (measured by severity of symptoms, quality of life, need for consultation, treatment, and hospital admission) is substantial. In the UK, 4·9% of admissions to one hospital were for heart failure, which would extrapolate to 120 000 admissions per year nationally if these single hospital data were representative,4 and such admissions continue to rise.5
Inhibitors of angiotensin-converting enzyme (ACE) improve both morbidity and mortality rates in all grades of symptomatic heart failure due to left-ventricular systolic dysfunction,6 and can delay or prevent progression of symptomless left-ventricular systolic dysfunction to symptomatic heart failure.7, 8 β blocker therapy also has substantial prognostic benefits in heart failure due to leftventricular systolic dysfunction.9 However, since few patients with suspected heart failure receive any assessment of left-ventricular function, heart failure is inadequately diagnosed and treated.10
In earlier work on prevalence of heart failure, researchers used clinical diagnostic criteria that are known to be inaccurate,11 especially early in the disease process. For example, diuretic prescription monitoring has produced widely differing estimates of heart failure prevalence, since not all patients taking diuretics have heart failure, and not all patients with heart failure might have presented for treatment.12 Investigations of prevalence of left-ventricular systolic dysfunction have also included objective assessment of left-ventricular function, usually by echocardiography.13 Such studies have indicated a prevalence of left ventricular systolic dysfunction of 2·9% in patients aged younger than 75 years13 and up to 7·5% in those aged 75–84 years,14 although this sample was not representative of the general population. However, no generalisable data are available for prevalence rates on left-ventricular systolic dysfunction prevalence rates in elderly people, or for those for heart failure due to other causes. We have used objective criteria to assess community prevalence of symptomatic and symptomless left-ventricular systolic dysfunction and investigated other causes of heart failure in a representative, general population aged 45 years or older.
Section snippets
Population
We stratified all primary care practices in the West Midlands region of England (population 5·3 million) into quartiles of the Townsend socioeconomic deprivation score15 of the populations they served. We then randomly selected four practices from each quartile (total 16 practices) for investigation. In seven practices, when it was either impractical to set up the screening clinic in the randomly selected practice or when participation was declined, we used an immediately neighbouring practice
Results
3960 (63%) of 6286 randomly selected patients responded to the postal invitation and underwent the full screening process. Reasons for the 2326 non-responses included too busy (25% [582]), not interested (15% [349]), already seeing other doctors (9% [209]), and scared to know the result (8% [186]). No further information is available about the disorders of the 9% of patients who were seeing another doctor. No significant differences were recorded between responders and nonresponders in age
Discussion
In our study, 72 (1·8%) people had either symptomless or symptomatic left-ventricular systolic dysfunction, and 54 (1·4%) people had definite heart failure from other causes. Thus the overall prevalence of prognostically significant cardiac dysfunction (heart failure from all causes, and symptomless left ventricular systolic dysfunction) is 3·2% (or 3·8% if probable heart failure is included).
Previous epidemiological studies on prevalence of heart failure have focused only on the most common
References (30)
Epidemiology of heart failure in the United States
Am Heart J
(1993)Epidemiological aspects of heart failure
Am Heart J
(1990)- et al.
Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population
Lancet
(1997) - et al.
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
Lancet
(1997) - et al.
Prognosis after recovery from first myocardial infarction: determinants of reinfarction and sudden death
Am J Cardiol
(1984) Effects of Enalapril on mortality in severe congestive heart failure
N Engl J Med
(1987)- et al.
The natural history of heart failure: the Framingham Study
N Engl J Med
(1971) Heart failure: a growing public health problem
J Intern Med
(1995)- et al.
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
JAMA
(1995) Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
N Engl J Med
(1992)
Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial
N Engl J Med
The Cardiac Insufficiency Bisoprolol Study II
Lancet
European survey of primary care physician perceptions and practice in heart failure diagnosis and management (Euro-HF study)
Eur Heart J
The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria
Circulation
Prevalence of heart failure in three general practices in North West London
Br J Gen Pract
Cited by (437)
Impact of air pollution on cardiovascular aging
2023, Mechanisms of Ageing and DevelopmentAcute Decompensated Aortic Stenosis: State of the Art Review
2023, Current Problems in CardiologyPrevalence and trends of type 2 diabetes mellitus and prediabetes among community-dwelling heart failure patients in the United States
2022, Diabetes Research and Clinical PracticeBiomarkers in Heart Failure: Clinical Insights
2021, Heart Failure ClinicsAmbient air pollution and asthma onset in Taiwanese adults
2020, Respiratory Medicine